China Resources Shuanghe announced that Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. Its 0.5g injectable methemicofol ester passed the consistent evaluation of generic drug quality and efficacy, and also agreed to changes in prescription processes, quality standards, packaging materials, and instructions. The drug is used to prevent acute organ rejection in patients with allogeneic kidney transplants or liver transplants. The company invested 2.903 million yuan in R&D. The drug is sold by an external partner unit, and there is a risk of uncertainty about contract performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.